Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen

Joseph Jelinski; Monika M. Kowatsch; Marc Alexandre Lafrance; Alice Berger; Jannie Pedersen; Hiva Azizi; Yue Li; Florine Scholte; Alejandro Gomez; Natasha Hollett; Toby Le; Matthew Wade; Hugues Fausther-Bovendo; Marc Antoine de La Vega; George Babuadze; Ara XIII; Claude Lamarre; Trina Racine; Chil Yong Kang; Xiao Jian Yao; Galit Alter; Eric Arts; Keith R. Fowke; Gary P. Kobinger

doi:10.1080/22221751.2023.2251595

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen

Joseph Jelinski, Monika M. Kowatsch, Marc Alexandre Lafrance, Alice Berger, Jannie Pedersen, Hiva Azizi, Yue Li, Florine Scholte, Alejandro Gomez, Natasha Hollett, Toby Le, Matthew Wade, Hugues Fausther-Bovendo, Marc Antoine de La Vega, George Babuadze, Ara XIII, Claude Lamarre, Trina Racine, Chil Yong Kang, Xiao Jian YaoGalit Alter, Eric Arts, Keith R. Fowke, Gary P. Kobinger

Microbiology And Immunology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.

Original language	English (US)
Article number	2251595
Pages (from-to)	2251595
Journal	Emerging Microbes and Infections
Volume	12
Issue number	2
DOIs	https://doi.org/10.1080/22221751.2023.2251595
State	Published - Dec 2023

Keywords

HIV
IFN-γ
NHP
T-cell
immunodeficiency
prophylaxis
vaccine

ASJC Scopus subject areas

Epidemiology
Parasitology
Microbiology
Immunology
Drug Discovery
Infectious Diseases
Virology

Access to Document

10.1080/22221751.2023.2251595

Cite this

Jelinski, J., Kowatsch, M. M., Lafrance, M. A., Berger, A., Pedersen, J., Azizi, H., Li, Y., Scholte, F., Gomez, A., Hollett, N., Le, T., Wade, M., Fausther-Bovendo, H., de La Vega, M. A., Babuadze, G., XIII, A., Lamarre, C., Racine, T., Kang, C. Y., ... Kobinger, G. P. (2023). Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen. Emerging Microbes and Infections, 12(2), 2251595. Article 2251595. https://doi.org/10.1080/22221751.2023.2251595

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen. / Jelinski, Joseph; Kowatsch, Monika M.; Lafrance, Marc Alexandre et al.
In: Emerging Microbes and Infections, Vol. 12, No. 2, 2251595, 12.2023, p. 2251595.

Research output: Contribution to journal › Article › peer-review

Jelinski, J, Kowatsch, MM, Lafrance, MA, Berger, A, Pedersen, J, Azizi, H, Li, Y, Scholte, F, Gomez, A, Hollett, N, Le, T, Wade, M, Fausther-Bovendo, H , de La Vega, MA , Babuadze, G, XIII, A, Lamarre, C, Racine, T, Kang, CY, Yao, XJ, Alter, G, Arts, E, Fowke, KR & Kobinger, GP 2023, 'Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen', Emerging Microbes and Infections, vol. 12, no. 2, 2251595, pp. 2251595. https://doi.org/10.1080/22221751.2023.2251595

@article{b558b4fd26a94bafb75ef61adaddddae,

title = "Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen",

abstract = "Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.",

keywords = "HIV, IFN-γ, NHP, T-cell, immunodeficiency, prophylaxis, vaccine",

author = "Joseph Jelinski and Kowatsch, {Monika M.} and Lafrance, {Marc Alexandre} and Alice Berger and Jannie Pedersen and Hiva Azizi and Yue Li and Florine Scholte and Alejandro Gomez and Natasha Hollett and Toby Le and Matthew Wade and Hugues Fausther-Bovendo and {de La Vega}, {Marc Antoine} and George Babuadze and Ara XIII and Claude Lamarre and Trina Racine and Kang, {Chil Yong} and Yao, {Xiao Jian} and Galit Alter and Eric Arts and Fowke, {Keith R.} and Kobinger, {Gary P.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd.",

year = "2023",

month = dec,

doi = "10.1080/22221751.2023.2251595",

language = "English (US)",

volume = "12",

pages = "2251595",

journal = "Emerging Microbes and Infections",

issn = "2222-1751",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen

AU - Jelinski, Joseph

AU - Kowatsch, Monika M.

AU - Lafrance, Marc Alexandre

AU - Berger, Alice

AU - Pedersen, Jannie

AU - Azizi, Hiva

AU - Li, Yue

AU - Scholte, Florine

AU - Gomez, Alejandro

AU - Hollett, Natasha

AU - Le, Toby

AU - Wade, Matthew

AU - Fausther-Bovendo, Hugues

AU - de La Vega, Marc Antoine

AU - Babuadze, George

AU - XIII, Ara

AU - Lamarre, Claude

AU - Racine, Trina

AU - Kang, Chil Yong

AU - Yao, Xiao Jian

AU - Alter, Galit

AU - Arts, Eric

AU - Fowke, Keith R.

AU - Kobinger, Gary P.

PY - 2023/12

Y1 - 2023/12

N2 - Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.

AB - Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.

KW - HIV

KW - IFN-γ

KW - NHP

KW - T-cell

KW - immunodeficiency

KW - prophylaxis

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85170088142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170088142&partnerID=8YFLogxK

U2 - 10.1080/22221751.2023.2251595

DO - 10.1080/22221751.2023.2251595

M3 - Article

C2 - 37649434

AN - SCOPUS:85170088142

SN - 2222-1751

VL - 12

SP - 2251595

JO - Emerging Microbes and Infections

JF - Emerging Microbes and Infections

IS - 2

M1 - 2251595

ER -

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this